Drug intelligence / Profile preview

vaspin

Development stage: Unknown
Modality: Peptides, Recombinant Proteins and Enzymes

Overview

Vaspin is a peptide hormone secreted by visceral adipose tissue, classified as an adipokine. It acts as a serine protease inhibitor and has been shown to reduce insulin resistance, potentially playing a protective role in metabolic disorders such as type 2 diabetes and cardiovascular disease. Vaspin is also being investigated for its role in lipid metabolism and its potential as a biomarker for adverse cardiac events[1][2][3].

Other names: visceral adipose tissue-derived serine protease inhibitorSERPINA12SERPINA-12SERPINA 12

Targets

HSPA5 (Heat shock protein family A member 5)KLK7

Beyond the preview

Go deeper on vaspin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vaspin.

Explore the full profile